Keith R Burgess1, Samuel J E Lucas2, Kelly Shepherd3, Andrew Dawson3, Marianne Swart3, Kate N Thomas2, Rebekah A I Lucas2, Joseph Donnelly2, Karen C Peebles2, Rishi Basnyat4, Philip N Ainslie5. 1. Peninsula Sleep Laboratory, Sydney, New South Wales, Australia and Department of Medicine, University of Sydney, Sydney, New South Wales, Australia. 2. University of Otago, Dunedin, New Zealand. 3. Peninsula Sleep Laboratory, Sydney, New South Wales, Australia. 4. Nepal International Clinic, Kathmandu, Nepal and Banner Good Samaritan Medical Center, Phoenix, Arizona. 5. Centre for Heart, Lung and Vascular Health, School of Health and Exercise Sciences, University of British Columbia, Okanagan Campus, Canada.
Abstract
STUDY OBJECTIVES: To further our understanding of central sleep apnea (CSA) at high altitude during acclimatization, we tested the hypothesis that pharmacologically altering cerebral blood flow (CBF) would alter the severity of CSA at high altitude. DESIGN: The study was a randomized, placebo-controlled single-blind study. SETTING: A field study at 5,050 m in Nepal. PATIENTS OR PARTICIPANTS: We studied 12 normal volunteers. INTERVENTIONS: Between days 5 to 10 at high altitude, CBF velocity (CBFv) was increased by intravenous (IV) acetazolamide (10 mg/kg) and reduced by oral indomethacin (100 mg). MEASUREMENTS AND RESULTS:Arterial blood gases, hypoxic and hypercapnic ventilatory responses, and CBFv and its reactivity to carbon dioxide were measured awake. Overnight polysomnography was performed. The central apnea-hypopnea index was elevated following administration of indomethacin (89.2 ± 43.7 to 112.5 ± 32.9 events/h; mean ± standard deviation; P < 0.05) and was reduced following IV acetazolamide (89.2 ± 43.7 to 47.1 ± 48.1 events/h; P < 0.001). Intravenous acetazolamide elevated CBFv at high altitude by 28% (95% confidence interval [CI]: 22-34%) but did not affect ventilatory responses. The elevation in CBFv was partly mediated via a selective rise in partial pressure of arterial carbon dioxide (PaCO2) (28 ± 4 to 31 ± 3 mm Hg) and an associated fall in pH (P < 0.01). Oral indomethacin reduced CBFv by 23% (95% CI: 16-30%), blunted CBFv reactivity, and increased the hypercapnic ventilatory response by 66% (95% CI: 30-102%) but had no effect on PaCO2 or pH. CONCLUSION: Our findings indicate an important role for cerebral blood flow regulation in the pathophysiology of central sleep apnea at high altitude.
RCT Entities:
STUDY OBJECTIVES: To further our understanding of central sleep apnea (CSA) at high altitude during acclimatization, we tested the hypothesis that pharmacologically altering cerebral blood flow (CBF) would alter the severity of CSA at high altitude. DESIGN: The study was a randomized, placebo-controlled single-blind study. SETTING: A field study at 5,050 m in Nepal. PATIENTS OR PARTICIPANTS: We studied 12 normal volunteers. INTERVENTIONS: Between days 5 to 10 at high altitude, CBF velocity (CBFv) was increased by intravenous (IV) acetazolamide (10 mg/kg) and reduced by oral indomethacin (100 mg). MEASUREMENTS AND RESULTS: Arterial blood gases, hypoxic and hypercapnic ventilatory responses, and CBFv and its reactivity to carbon dioxide were measured awake. Overnight polysomnography was performed. The central apnea-hypopnea index was elevated following administration of indomethacin (89.2 ± 43.7 to 112.5 ± 32.9 events/h; mean ± standard deviation; P < 0.05) and was reduced following IV acetazolamide (89.2 ± 43.7 to 47.1 ± 48.1 events/h; P < 0.001). Intravenous acetazolamide elevated CBFv at high altitude by 28% (95% confidence interval [CI]: 22-34%) but did not affect ventilatory responses. The elevation in CBFv was partly mediated via a selective rise in partial pressure of arterial carbon dioxide (PaCO2) (28 ± 4 to 31 ± 3 mm Hg) and an associated fall in pH (P < 0.01). Oral indomethacin reduced CBFv by 23% (95% CI: 16-30%), blunted CBFv reactivity, and increased the hypercapnic ventilatory response by 66% (95% CI: 30-102%) but had no effect on PaCO2 or pH. CONCLUSION: Our findings indicate an important role for cerebral blood flow regulation in the pathophysiology of central sleep apnea at high altitude.
Authors: Henry Krum; Michael V Jelinek; Simon Stewart; Andrew Sindone; John J Atherton; Anna L Hawkes Journal: Med J Aust Date: 2006-11-20 Impact factor: 7.738
Authors: Keith Burgess; Katie Burgess; Prajan Subedi; Phil Ainslie; Zbigniew Topor; William Whitelaw Journal: Adv Exp Med Biol Date: 2008 Impact factor: 2.622
Authors: Ailiang Xie; James B Skatrud; Barbara Morgan; Bruno Chenuel; Rami Khayat; Kevin Reichmuth; Jenny Lin; Jerome A Dempsey Journal: J Physiol Date: 2006-08-24 Impact factor: 5.182
Authors: T Douglas Bradley; Alexander G Logan; R John Kimoff; Frédéric Sériès; Debra Morrison; Kathleen Ferguson; Israel Belenkie; Michael Pfeifer; John Fleetham; Patrick Hanly; Mark Smilovitch; George Tomlinson; John S Floras Journal: N Engl J Med Date: 2005-11-10 Impact factor: 91.245
Authors: Ailiang Xie; James B Skatrud; Rami Khayat; Jerome A Dempsey; Barbara Morgan; Douglas Russell Journal: Am J Respir Crit Care Med Date: 2005-05-18 Impact factor: 21.405
Authors: Buddha Basnyat; Jeffrey H Gertsch; Peter S Holck; E William Johnson; Andrew M Luks; Benjamin P Donham; Ross J Fleischman; Daniel W Gowder; Jason S Hawksworth; Brett T Jensen; Richard J Kleiman; Adam H Loveridge; Elizabeth B Lundeen; Sheri L Newman; Jesse A Noboa; Daniel P Miegs; Kenneth A O'Beirne; Kelly B Philpot; Miriam N Schultz; Matthew C Valente; Mandie R Wiebers; Erik R Swenson Journal: High Alt Med Biol Date: 2006 Impact factor: 1.981
Authors: Ryan L Hoiland; Philip N Ainslie; Kevin W Wildfong; Kurt J Smith; Anthony R Bain; Chris K Willie; Glen Foster; Brad Monteleone; Trevor A Day Journal: J Physiol Date: 2015-01-14 Impact factor: 5.182